|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Deficiency, vitamin K |
|
Hemorrhagic disease of the newborn |
|
Hypoprothrombinemia |
|
Toxicity, coumarin |
| |
|
|
SIDE EFFECTS:
|
|
anaphylactic shock |
|
anaphylactoid reactions |
|
bronchospasm |
|
cardiac arrest |
|
cyanosis |
|
diaphoresis |
|
dizziness |
|
dysgeusia |
|
dyspnea |
|
erythema |
|
flushing |
|
hemolysis |
|
hyperbilirubinemia |
|
hypotension |
|
injection site reaction |
|
jaundice |
|
pruritus |
|
respiratory arrest |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
anticoagulant therapy |
|
biliary tract disease |
|
breast-feeding |
|
children |
|
hepatic disease |
|
hypoprothrombinemia |
|
intramuscular administration |
|
intravenous administration |
|
jaundice |
|
neonates |
|
pregnancy |
|
|
ADULT DOSE:
|
|
Hypoprothrombinemia, anticoagulant-induced (coumarin- or indanedione-derivative)-
Oral, 2.5 to 10 mg, or up to 25 mg (rarely up to 50 mg) ; subsequent doses should be determined by prothrombin time (PT) response and/or clinical condition .
Hypoprothrombinemia due to other causes-
Oral, 2.5 to 25 mg or more (rarely up to 50 mg); the amount administered depends on the severity of the condition and the clinical and/or PT response obtained . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|